Advisors Preferred LLC Makes New $2.02 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Advisors Preferred LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 42,162 shares of the biopharmaceutical company’s stock, valued at approximately $2,024,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. RPg Family Wealth Advisory LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $1,886,000. Segall Bryant & Hamill LLC boosted its stake in Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after buying an additional 49,856 shares in the last quarter. Retirement Systems of Alabama increased its holdings in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the period. South Street Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $9,812,000. Finally, Foster & Motley Inc. lifted its holdings in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after acquiring an additional 12,630 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $57.10 on Friday. The business’s 50 day moving average is $51.37 and its 200-day moving average is $54.40. The firm has a market cap of $7.26 billion, a P/E ratio of 18.91, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1-year low of $34.36 and a 1-year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.